Oruka Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +123.2% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 9.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -24.9% | Better than 15% |
| Return on invested capital | -28.7% | Better than 10% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -11.3% | Better than 48% |
| 6-month return | 58.1% | Better than 96% |
| 12-month return (ex latest month) | 173.6% | Better than 98% |
| Distance below 52-week high | 17.1% | Better than 67% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 22.4x | Better than 98% |
| Debt to assets | 0.4% | Better than 96% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 54.9% | Better than 69% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 97.57
- Open
- 95.86
- Day range
- 93.30 - 97.24
- Avg price
- 95.11
- Volume
- 1.98M
- Turnover
- 188.03M
- Turnover ratei
- 3.37%
- Volume ratioi
- 2.52
- Amplitudei
- 4.03%
- 52-week rangei
- 25.23 - 115.52
Valuation
- P/Ei
- -51.79
- P/E (TTM)i
- -45.19
- P/Bi
- 5.44
- EPSi
- -1.85
- Book value / shi
- 17.62
- Net profit
- -125.47M
- Net assets
- 1.20B
Share structure
- Market cap
- 6.50B
- Float capi
- 5.61B
- Shares out
- 67.82M
- Float sharesi
- 58.60M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
17.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-54.91M net over the window
Short interest
- Shares short
- 6.46M
- % of floati
- 9.76%
- Days to coveri
- 7.06
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Oruka Therapeutics (ORKA)?
Oruka Therapeutics last traded at 95.81. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Oruka Therapeutics's market cap?
About 6.50B.
What is the P/E ratio of Oruka Therapeutics?
The trailing twelve-month P/E is -45.19. The Valuation tab shows it against the stock's own five-year range.
Does Oruka Therapeutics pay a dividend?
Oruka Therapeutics does not currently pay a regular dividend.
Is Oruka Therapeutics a buy according to analysts?
The consensus of 11 analysts is a Buy rating, with an average 12-month price target of 148.44, which implies 54.9% upside from the current price. This is not investment advice.
What is Oruka Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Oruka Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.
Oruka Therapeutics discussion 0 comments